Delivering Functional Annotation for Precision Cancer Treatment

For PharmaFor Clinicians

Unmet Need in Personalized Medicine

Genome sequencing techniques reveal mutations but provide no knowledge whether the translated protein is actually aberrantly activated. This is because the functional significance of most mutations is unknown, let alone that of networks of interacting proteins. NovellusDx leverages its live cell based assay to complement the power of NGS with actionable insights on the affected signaling pathways.

Home

Each cancer patient has a unique mutational tumor profile, hence requiring a targeted treatment strategy

Home  Home

High costs of personalized medicine confers tremendous economic and social burden

Home  Home  Home

Cancer is the deregulation of signaling pathways; sequencing methods are unable to analyze their activity

Home  Home  Home  Home

Functional annotation of signaling pathways is essential to guide treatment strategy in an evidence-based manner

Fully automated, high-throughput, high-content live-cell screening straight from NGS data.

Once we receive the NGS data, we resynthesize the genes with all the mutations - driver, passenger and VUS - and express them in a cell-line. After an incubation period, the cells are scanned in a high-content microscopy system and analyzed using our proprietary algorithms to determine the localization of specific downstream reporters inside the cells. This tells us the activity level of each signaling pathway. We then repeat the process with the incubation of targeted therapies which allows us to assess drug response.

Home  Home  Home  Home  Home

Physician sends NovellusDx NGS data or fresh biopsy

Home  Home  Home  Home  Home  Home

Patient tailored fluorescent live-cell chip is printed on slides

Home  Home  Home  Home  Home  Home  Home

Automatic high content image analysis of signaling pathways activation

Home  Home  Home  Home  Home  Home  Home  Home

Results and data integration to actionable report for the physicians

Home  Home  Home  Home  Home

Physician sends NovellusDx NGS data or fresh biopsy

Home  Home  Home  Home  Home  Home

Patient tailored fluorescent live-cell chip is printed on slides

Home  Home  Home  Home  Home  Home  Home

Automatic high content image analysis of signaling pathways activation

Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home

Repeat process with targeted drugs and drug combination testing

Home  Home  Home  Home  Home  Home  Home  Home

Results and data integration to actionable report for the physicians


Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home

Repeat process with targeted drugs and drug combination testing

NovellusDx Added-Value Over Sequencing

Actionable clinical insights using live cell-based system

Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home

DRIVER MUTATION DISCOVERY

Functional characterization of mutation previously annotated as Variants of Uncertain Significance (VUS)

Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home

RESPONSE TO TARGETED THERAPY

Examine the potential response of patients to targeted drugs and drug combinations

Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home  Home

DETECT RESISTANCE MECHANISMS

Analyze the unique mutational network of every patient to detect resistance mechanisms

We use high-throughput cellular analysis of genes constituting the signal transduction pathways to bring you the most actionable information

Cells Analyzed (K)

Genes Covered

%

Targeted Therapies Covered

For Oncologist

NovellusDx provides clinicians and patients functional information to supplement their genomic data and tests targeted therapies efficacy on their specific genomic profiles.

Learn More

For Pharma

NovellusDx is the trusted partner for BioPharma, providing services and support for functional genomic informed oncology drug development and commercialization.

Learn More

News & Events

Management

Investors